ASIA PACIFIC IN-VITRO FERTILIZATION MARKET FORECAST 2017-2026
KEY FINDINGS
The Asia-Pacific in-vitro fertilization (IVF) market is forecasted to rise with 12.50% CAGR over the estimated period of 2017-2026. The market is expected to hold much promise for the overall global IVF market, increasing its revenue from $3124 million to $10000 million over the said period.
MARKET INSIGHTS
The cost of IVF procedures is quite cheap in Asia-Pacific as compared to other regional markets. Hence the region is also being preferred by people all over the world for IVF treatments. Perhaps this is the reason that the Asia-Pacific IVF market is slated to showcase the highest CAGR increase for the forecast period as compared to other regional markets. Investments from private equity investors for further advancement in research and development in IVF techniques in this area are providing substantial growth opportunities for the market to grow. However, in some of these Asia-Pacific countries, male infertility is considered as a social taboo which refrains them from using the IVF methods. Instead, they prefer to go for traditional treatments to solve this problem. These factors could possibly restrict the growth of the Asia-Pacific market in the coming years.
COMPETITIVE INSIGHTS
Halotech DNA, Thermo Fisher Scientific Inc, Auxogyn, Copper Surgical Inc, Ovascience, Vitrolife Ab, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Cook Medical Inc, Genea, Merck Serono, Andrology Solutions, Esco Micro Pte. Ltd, Ferring Pharmaceuticals, and Ivftech Aps are some of the top companies engaged in this market.
The Asia-Pacific in-vitro fertilization (IVF) market is forecasted to rise with 12.50% CAGR over the estimated period of 2017-2026. The market is expected to hold much promise for the overall global IVF market, increasing its revenue from $3124 million to $10000 million over the said period.
MARKET INSIGHTS
The cost of IVF procedures is quite cheap in Asia-Pacific as compared to other regional markets. Hence the region is also being preferred by people all over the world for IVF treatments. Perhaps this is the reason that the Asia-Pacific IVF market is slated to showcase the highest CAGR increase for the forecast period as compared to other regional markets. Investments from private equity investors for further advancement in research and development in IVF techniques in this area are providing substantial growth opportunities for the market to grow. However, in some of these Asia-Pacific countries, male infertility is considered as a social taboo which refrains them from using the IVF methods. Instead, they prefer to go for traditional treatments to solve this problem. These factors could possibly restrict the growth of the Asia-Pacific market in the coming years.
COMPETITIVE INSIGHTS
Halotech DNA, Thermo Fisher Scientific Inc, Auxogyn, Copper Surgical Inc, Ovascience, Vitrolife Ab, Irvine Scientific (Subsidiary Of Nippon Mining Holdings), Cook Medical Inc, Genea, Merck Serono, Andrology Solutions, Esco Micro Pte. Ltd, Ferring Pharmaceuticals, and Ivftech Aps are some of the top companies engaged in this market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC SHOWS GREAT PROMISE FOR THE FORECAST PERIOD
3.2.2. INSURANCE COVERAGE FOR IVF
3.2.3. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTERS 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. REGIONAL OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. CHINA
8.2. INDIA
8.3. JAPAN
8.4. AUSTRALIA
8.5. REST OF ASIA-PACIFIC
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ASIA PACIFIC SHOWS GREAT PROMISE FOR THE FORECAST PERIOD
3.2.2. INSURANCE COVERAGE FOR IVF
3.2.3. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTERS 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. REGIONAL OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. CHINA
8.2. INDIA
8.3. JAPAN
8.4. AUSTRALIA
8.5. REST OF ASIA-PACIFIC
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
LIST OF TABLES
Table 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 ASIA PACIFIC IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 ASIA PACIFIC IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 ASIA PACIFIC IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 ASIA PACIFIC IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 ASIA PACIFIC IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 ASIA PACIFIC IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 ASIA PACIFIC IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 ASIA PACIFIC IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 ASIA PACIFIC IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 ASIA PACIFIC IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
LIST OF FIGURES
Figure 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 ASIA PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 3 EVOLUTION OF IVF MARKET
Figure 4 ASIA PACIFIC REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 ASIA PACIFIC EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 ASIA PACIFIC INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 ASIA PACIFIC PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 ASIA PACIFIC FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 ASIA PACIFIC OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 ASIA PACIFIC FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 ASIA PACIFIC HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 ASIA PACIFIC CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR ASIA PACIFIC IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR ASIA PACIFIC IVF MARKET BY END-USER - 2016
Figure 15 CHINA IVF MARKET 2017-2026 ($ MILLION)
Figure 16 INDIA IVF MARKET 2017-2026 ($ MILLION)
Figure 17 JAPAN IVF MARKET 2017-2026 ($ MILLION)
Figure 18 AUSTRALIA IVF MARKET 2017-2026 ($ MILLION)
Figure 19 REST OF ASIA-PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 20 ASIA PACIFIC IVF MARKET SHARE OF MAJOR COMPANIES – 2016
Figure 1 ASIA PACIFIC IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 ASIA PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 3 EVOLUTION OF IVF MARKET
Figure 4 ASIA PACIFIC REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 ASIA PACIFIC EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 ASIA PACIFIC INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 ASIA PACIFIC PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 ASIA PACIFIC FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 ASIA PACIFIC OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 ASIA PACIFIC FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 ASIA PACIFIC HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 ASIA PACIFIC CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR ASIA PACIFIC IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR ASIA PACIFIC IVF MARKET BY END-USER - 2016
Figure 15 CHINA IVF MARKET 2017-2026 ($ MILLION)
Figure 16 INDIA IVF MARKET 2017-2026 ($ MILLION)
Figure 17 JAPAN IVF MARKET 2017-2026 ($ MILLION)
Figure 18 AUSTRALIA IVF MARKET 2017-2026 ($ MILLION)
Figure 19 REST OF ASIA-PACIFIC IVF MARKET 2017-2026 ($ MILLION)
Figure 20 ASIA PACIFIC IVF MARKET SHARE OF MAJOR COMPANIES – 2016
